Apogee Therapeutics Inc (NASDAQ:APGE) shares, rose in value on Thursday, April 16, with the stock price up by 3.34% to the previous day’s close as strong demand from buyers drove the stock to $33.11.
Actively observing the price movement in the last trading, the stock closed the session at $32.04, falling within a range of $31.6 and $33.38. Referring to stock’s 52-week performance, its high was $63.50, and the low was $26.20. On the whole, APGE has fluctuated by -18.13% over the past month.
With the market capitalization of Apogee Therapeutics Inc currently standing at about $1.97 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-02.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that APGE’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of APGE currently trading nearly -5.90% and -7.17% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 45.63, while the 7-day volatility ratio is showing 7.71% which for the 30-day chart, stands at 8.83%. Furthermore, Apogee Therapeutics Inc (APGE)’s beta value is 1.88, and its average true range (ATR) is 3.01.
A comparison of Apogee Therapeutics Inc (APGE) with its peers suggests the former has fared considerably weaker in the market. APGE showed an intraday change of 3.34% in last session, and over the past year, it shrunk by -34.64%%.
Data on historical trading for Apogee Therapeutics Inc (NASDAQ:APGE) indicates that the trading volumes over the past 10 days have averaged 0.89 and over the past 3 months, they’ve averaged 689.19K. According to company’s latest data on outstanding shares, there are 45.99 million shares outstanding.
Nearly 37.59% of Apogee Therapeutics Inc’s shares belong to company insiders and institutional investors own 81.95% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 8.63 million shares as on 2025-03-31, resulting in a short ratio of 10.96. According to the data, the short interest in Apogee Therapeutics Inc (APGE) stood at 2166.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 7.76 million. The stock has fallen by -26.91% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the APGE stock heading into the next quarter.
